Syndax Announces Participation in February Investor Conferences
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in February 2025. CEO Michael A. Metzger and the management team will attend:
1. The Guggenheim SMID Cap Biotech Conference in New York, featuring a fireside chat on February 6, 2025, at 10:30 a.m. ET
2. Citi's 2025 Virtual Oncology Leadership Summit, with a fireside chat scheduled for February 19, 2025, at 9:00 a.m. ET
Both presentations will be available via webcast on the company's website investor section, with replays accessible for a time.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata sulle terapie per il cancro, ha annunciato la sua partecipazione a due conferenze per investitori previste per febbraio 2025. Il CEO Michael A. Metzger e il team di gestione parteciperanno:
1. La Guggenheim SMID Cap Biotech Conference a New York, con una chiacchierata informale il 6 febbraio 2025, alle 10:30 ET
2. Il Citi's 2025 Virtual Oncology Leadership Summit, con una chiacchierata informale programmata per il 19 febbraio 2025, alle 9:00 ET
Entrambe le presentazioni saranno disponibili tramite webcast nella sezione investitori del sito web dell'azienda, con riproduzioni accessibili per un periodo di tempo.
Syndax Pharmaceuticals (NASDAQ: SNDX), una compañía biofarmacéutica en etapa comercial enfocada en terapias contra el cáncer, ha anunciado su participación en dos próximas conferencias de inversores en febrero de 2025. El CEO Michael A. Metzger y el equipo de gestión asistirán a:
1. La Conferencia de Biotecnología SMID Cap de Guggenheim en Nueva York, que contará con una charla informal el 6 de febrero de 2025, a las 10:30 a.m. ET
2. La Cumbre Virtual de Liderazgo en Oncología de Citi 2025, con una charla informal programada para el 19 de febrero de 2025, a las 9:00 a.m. ET
Ambas presentaciones estarán disponibles a través de un webcast en la sección para inversores del sitio web de la empresa, con reproducciones accesibles por un tiempo limitado.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 암 치료에 중점을 둔 상업 단계의 생명공학 회사로, 2025년 2월에 열릴 두 개의 투자자 회의에 참여한다고 발표했습니다. CEO인 Michael A. Metzger와 경영팀이 참석할 예정입니다:
1. 뉴욕에서 열리는 Guggenheim SMID Cap Biotech Conference, 2025년 2월 6일 오전 10시 30분 ET에 진행되는 파이어사이드 채팅 포함
2. Citi의 2025년 가상 종양학 리더십 정상 회담, 2025년 2월 19일 오전 9시에 예정된 파이어사이드 채팅
두 프레젠테이션은 회사 웹사이트의 투자자 섹션을 통해 웹캐스트로 제공되며, 재생은 일정 기간 동안 가능합니다.
Syndax Pharmaceuticals (NASDAQ: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur les thérapies contre le cancer, a annoncé sa participation à deux conférences pour investisseurs prévues en février 2025. Le CEO Michael A. Metzger et son équipe de direction assisteront :
1. La Conférence Biotech SMID Cap de Guggenheim à New York, avec une discussion informelle le 6 février 2025 à 10h30 ET
2. Le Sommet Virtuel de Leadership en Oncologie de Citi 2025, avec une discussion informelle prévue pour le 19 février 2025 à 9h00 ET
Les deux présentations seront disponibles via un webinaire dans la section investisseurs du site web de l'entreprise, avec des rediffusions accessibles pour une durée limitée.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf Krebstherapien, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Februar 2025 angekündigt. CEO Michael A. Metzger und das Managementteam werden teilnehmen:
1. Die Guggenheim SMID Cap Biotech Conference in New York, die am 6. Februar 2025, um 10:30 Uhr ET eine informelle Diskussion umfasst
2. Der Citi's 2025 Virtuelle Onkologie-Leitungsgipfel, mit einer informellen Diskussion, die für den 19. Februar 2025, um 9:00 Uhr ET geplant ist
Beide Präsentationen sind über Webcast im Investorenbereich der Unternehmenswebsite verfügbar, mit Wiedergaben, die für eine bestimmte Zeit zugänglich sind.
- None.
- None.
- Guggenheim SMID Cap Biotech Conference in
New York, NY with a fireside chat on Thursday, February 6, 2025, at 10:30 a.m. ET - Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025, at 9:00 a.m. ET
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-february-investor-conferences-302363686.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When is Syndax (SNDX) presenting at the Guggenheim SMID Cap Biotech Conference in 2025?
When is Syndax (SNDX) participating in Citi's 2025 Virtual Oncology Leadership Summit?
Where can investors watch Syndax's (SNDX) February 2025 conference presentations?